系统性硬化症相关的间歇性肺部疾病的治疗响应生物标志物
Elizabeth R Volkmann1, Holly Wilhalme1, Donald P Tashkin1
1University of California, Los Angeles.
Arthritis care & research
|December 23, 2024
概括
克雷布斯登肺 (KL) - 6水平的变化预测了系统性硬化症相关的间歇性肺病 (SSc-ILD) 患者的渐进性肺纤维化 (PPF). 这种生物标志物有助于个性化SSc-ILD治疗策略.
科学领域:
- 类风湿病学 类风湿病学
- 肺部病理学 肺部病理学
- 生物标志物发现发现
背景情况:
- 系统性硬化症相关的间歇性肺病 (SSc-ILD) 是发病率和死亡率的重要原因.
- 在SSc-ILD患者中预测渐进性肺纤维化 (PPF) 对于及时的治疗干预至关重要.
- 目前的PPF预测模型需要通过动态生物标志物进行增强.
研究的目的:
- 调查循环生物标志物的变化对于接受治疗的SSc-ILD患者中PPF的发展的预测价值.
- 评估纵向生物标志物测量的实用性,以完善PPF风险分层.
主要方法:
- 来自 II 肺硬化症研究参与者的纵向生物标记数据 (CRP,IL-6,CXCL4,CCL18,KL-6) 的分析.
- 菌酸莫菲蒂尔 (MMF) 与环胺 (CYC) 治疗臂的比较.
- 后勤回归建模以评估生物标志物变化与PPF发展之间的关联24个月.
主要成果:
- 克雷布斯登肺 (KL) - 6水平的变化与PPF发展有显著的相关性 (P < 0.001).
- 在开发PPF的患者中观察到KL-6变化升高,而在没有开发PPF的患者中观察到下降.
- 在MMF手臂中,C-反应蛋白 (CRP) 和CXCL4的变化也与PPF相关;当添加到基线模型时,KL-6的变化仍然是一个显著的预测因素 (OR 1.4;P = 0.0002).
结论:
- KL-6水平的纵向变化有效地预测了SSc-ILD患者的PPF,这些患者接受MMF或CYC治疗.
- KL-6 作为一个有价值的动态生物标志物,用于评估纤维化进展.
- 将KL-6监测纳入临床实践可能使SSc-ILD的个性化治疗策略成为可能.
相关概念视频
COPD: Management Using Bronchodilators and Corticosteroids
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
Pneumonia IV: Management
The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Pulmonary Tuberculosis I
Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Pulmonary Tuberculosis V
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
Chronic Obstructive Pulmonary Disease-V: Management
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
Smoking Cessation
Myocarditis III: Medical Management
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...


